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Abstract
Background: The eradication rate of Helicobacter pylori (H. pylori) with triple therapy which was considered as
standard first-line treatment has decreased to 70–85%. The aim of this study is to compare 7-day triple therapy
versus 10-day sequential therapy as the first line treatment.
Methods: Data of 1240 H. pylori positive patients treated with triple therapy or sequential therapy from January
2013 to December 2015 were analyzed retrospectively. The patients who had undertaken previous H. pylori
eradication therapy or gastric surgery were excluded.
Results: There were 872 (74.3%) patients in the triple therapy group, and 302 (25.7%) patients in the sequential
therapy group. There was no significant difference between the two groups regarding age, residence, comorbidities
or drug compliance, but several differences were noted in endoscopic characteristics and indication for the
treatment. The eradication rate of H. pylori by intention to treat analysis was 64.3% in the triple therapy group, and
81.9% in the sequential therapy group (P = 0.001). In per protocol analysis, H. pylori eradication rate in the triple
therapy and sequential therapy group was 81.9 and 90.3%, respectively (P = 0.002). There was no significant
difference in overall adverse events between the two groups (P = 0.706). For the rescue therapy, bismuth-containing
quadruple therapy showed comparable treatment efficacy after sequential therapy, as following triple therapy.
Conclusions: The eradication rate of triple therapy was below the recommended threshold. Sequential therapy
could be effective and tolerable candidate for the first-line H. pylori eradication therapy.
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Background
The prevalence of Helicobacter pylori (H. pylori) infec-
tion has decreased over the past decade, changed from
66.9 to 54.4% between 1998 and 2011, but its prevalence
is still high in Korea [1]. H. pylori infection is a known
risk factor of upper gastrointestinal diseases, such as
chronic gastritis, peptic ulcer disease, mucosa-associated
lymphoid tissue (MALT) lymphoma, and gastric cancer
[2, 3]. Eradication of H. pylori reduces the recurrence
rate of peptic ulcer disease or recurrent gastric cancer
after endoscopic resection of early gastric cancer, and it
also induces the remission of MALT lymphoma [4–6].
Therefore, H. pylori eradication has critical role in
promoting national health in Korea, where 95% of con-
firmed H. pylori strains have highly virulent East Asian-
type cytotoxin-associated gene A which is potent in
causing gastric cancer [7, 8].
Triple therapy (TT) consists of proton-pump inhibitor
(PPI), clarithromycin, and amoxicillin has been consid-
ered as standard first-line treatment for H. pylori in
Korea since 1998 [9]. Recently updated Korean guideline
also recommended TT as the first-line regimen [10].
However, the efficacy of TT has decreased progressively.
The recent nationwide survey reported the decreasing
trend of eradication rate of TT which was 84.9–87.5%
from 2001 to 2007, but 80.0–81.4% from 2008 to
2010 (P < 0.0001) [11]. The most important factor of
reduced efficacy of TT is increasing antibiotic resist-
ance of H. pylori, especially to clarithromycin [12]. The
primary resistance rate to clarithromycin increased from
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23.7 to 71.2%, whereas amoxicillin increased from 6.3 to
14.9% during the period of 2003–2012 [13].
Therefore, several protocols have been suggested in
order to overcome treatment failure of TT, including the
extending of treatment duration, the use of four-drug
regimen such as sequential therapy (SET), concomitant
therapy, hybrid therapy, and the prescription of novel
antibiotics such as levofloxacin [14]. Reasonable treat-
ment regimens need to attain H. pylori eradication rate
of higher than 80.0% by intention to treat (ITT) analysis,
and higher than 90.0% by per protocol (PP) analysis
[15, 16]. Several previous meta-analyses reported the
superiority of SET than TT [17, 18], whereas other
studies revealed conflicting results [19, 20].
In Ewha Womans University Medical Center, SET
has been tried as an alternative first-line treatment for
H. pylori since 2013. So, we aimed to compare 7-day
TT with 10-day SET as the first line treatment in our
medical center. We also evaluated the adverse events
of the two regimens, clinical factors associated with
successful eradication, and effectiveness of the second
line treatment after these two treatments.
Methods
Study subjects
From January 2013 to December 2015, 1240 patients
who were older than 18-year old, diagnosed with H. pylori
infection and treated with TT or SET at Ewha Womans
University Hospital were enrolled retrospectively. H. pylori
infection was confirmed by histology, rapid urease test
(HP Kit™, Jongkeundang, Korea), C-urea breath test or
serum H. pylori anti-body test. At least 4 weeks after
treatment, H. pylori eradication was demonstrated by any
of these tests. The patients who had undertaken previous
H. pylori eradication therapy or gastric surgery were
excluded.
We evaluated demographic information, residence
area, current status of smoking and alcohol consump-
tion, comorbidities, endoscopic diagnosis, indication for
H. pylori eradication, drug compliance, and treatment-
related adverse events through medical records review.
Endoscopic findings and the results of endoscopic biop-
sies were also reviewed retrospectively. For detailed ana-
lysis, drug compliance was divided into two categories;
good or poor compliance. Good compliance was defined
if the patient took more than 80% of the prescribed
medicine, and who took less than 80% of prescribed
medicine was belonged to poor compliance group. For
the PP analysis, patients who were poorly compliant or
lost to follow-up were excluded.
Standard TT for seven days consists of twice a day
amoxicillin (1000 mg), clarithromycin (500 mg), and
standard dose of PPI. SET for 10 days consists of twice a
day amoxicillin (1000 mg), standard dose of PPI for
5 days, followed by twice a day clarithromycin (500 mg),
metronidazole (500 mg), and standard dose of PPI for
another 5 days.
This study was approved by the Institutional Review
Board of our medical center (IRB number; 2016-04-
051-002).
Statistical analyses
All statistical analyses were performed with using SPSS
program, version 22.0. Continuous variables were re-
ported as the mean with the standard deviation. To
analyze the baseline clinical characteristics, adverse
events and eradication rates between the two groups,
Student t-test or the Mann-Whitney U test was used for
continuous variables, and the chi-square or the Fisher’s
exact test was used for categorical variables. H. pylori
eradication rates were demonstrated by ITT and PP
analyses. Univariate and multivariate logistic regression
were performed for evaluating independent associated
factors with successful H. pylori eradication. The P value
of < 0.05 was considered as statistical significance.
Results
Baseline characteristics
A total of 1240 patients received H. pylori eradication
therapy from January 2013 to December 2015. After ex-
cluding 66 patients who had previous H. pylori eradica-
tion or gastric surgery, 1174 patients were included
finally. There were 872 patients in the TT group and 302
patients in the SET group. A detailed flowchart of the
enrolled patients is shown in Fig. 1. The baseline charac-
teristics of the study population are summarized in
Table 1. There was no significant difference between the
two groups regarding age, residence, comorbidities or
drug compliance. But, more males and more patients
who were diagnosed with H. pylori infection by histology
were included in the SET group than the TT group.
Several differences were found in the endoscopic
Fig. 1 The flowchart of enrolled patients. H. pylori Helicobacter pylori,
Jan January, Dec December, TT triple therapy, SET sequential therapy
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characteristics - atrophy or metaplastic gastritis (P = 0.009),
and gastric ulcers (P = 0.011) were more prevalent in the
SET group, whereas chronic gastritis (P < 0.001) and duo-
denal ulcers (P = 0.008) were more prevalent in the TT
group. In terms of indication of H. pylori eradication, sig-
nificantly higher portion of patients received SET after
endoscopic resection of gastric neoplasms such as early
gastric cancers (P < 0.001) or gastric adenomas (P = 0.009).
H. pylori eradication rates
Among 872 patients receiving first-line TT, 684 (78.4%)
patients completed the treatment with good compliance.
In the SET group, 248 (82.1%) patients completed the
treatment with good compliance in total of 302 patients.
The eradication rate of SET was significantly higher than
TT by both ITT (P = 0.001) and PP (P = 0.002) analyses.
The TT showed the eradication rate of 64.3 and 81.9%
by ITT and PP analyses, respectively. The overall eradi-
cation rate of SET was 81.9 in ITT, and 90.3% in PP ana-
lysis (Fig. 2).
Clinical factors related to the H. pylori eradication
Possible clinical factors related to successful H. pylori
eradication were also analyzed. But, there were no statis-
tically significant factors to predict successful eradication
in both univariate and multivariate analyses (Table 2).
Comparison of treatment-related adverse events
During the treatment, 33 (3.8%) patients in the TT
group, and 10 (3.3%) patients in the SET group had
treatment-related adverse events. The most common ad-
verse event was diarrhea (1.3% versus (vs.) 1.7%; TT vs.
SET), followed by nausea or vomiting in both groups.
But, there was no significant difference in the rate of
specific adverse event as well as overall adverse events
between the two groups (Table 3).
Second-line eradication therapy after first-line eradication
failure
A detailed flow-chart of second-line eradication therapy
after failure of first-line eradication therapy is shown in
Fig. 3. Among 124 (18.1%) patients who failed in first-
line TT, 109 patients received second-line eradication
therapy; 28.4% for bismuth-containing quadruple ther-
apy (BCQT) for 7 days (BCQT-7), 68.8% for BCQT for
14 days (BCQT-14), and 2.8% of patients for TT for
7 days. Data from the patients who received second-line
TT could not be included for further analyses because of
poor compliance or loss of follow-up. The eradication
rate in patients who received BCQT-7 after failing
Table 1 Baseline clinical characteristics





Age (mean ± SD) 52.26± 13.52 51.83 ± 12.17 0.607
Male 477 (54.7) 192 (63.6) 0.007
Residence 0.510
Seoul 695 (79.7) 246 (81.5)
Another area 177 (20.3) 56 (18.5)
Smoking 217 (24.9) 113 (37.4) <0.001
Alcohol 389 (41.3) 91 (39.2) <0.001
Diabetes mellitus 98 (11.2) 33 (10.9) 0.882
Hypertension 185 (21.2) 71 (23.5) 0.405
Chronic kidney disease 12 (1.4) 4 (1.3) 0.999
Chronic liver disease 24 (2.8) 7 (2.3) 0.685
Ischemic heart disease 23 (2.6) 12 (4.0) 0.239
Compliance > 80% 707 (81.1) 256 (84.8) 0.150
H. pylori test <0.001
Histology 293 (33.6) 182 (60.3)
Rapid urease test 586 (64.9) 116 (38.4)
Urea breath test 8 (0.9) 2 (0.7)
Serology 5 (0.6) 2 (0.7)
Endoscopic diagnosis
Chronic gastritis 201 (23.1) 31 (10.3) <0.001
Atrophy or metaplasia 332 (38.1) 141 (46.7) 0.009
Gastric ulcer 274 (31.4) 119 (39.4) 0.011
Duodenal ulcer 331 (38.0) 89 (29.5) 0.008
Duodenitis 52 (6.0) 18 (6.0) 0.998
Indication of H. pylori eradication
Peptic ulcer disease 522 (59.9) 148 (49.0) 0.001
Endoscopic resection of EGC 21 (2.4) 24 (7.9) <0.001
Endoscopic resection of adenoma 36 (4.1) 24 (7.9) 0.009
MALT lymphoma 4 (0.5) 2 (0.7) 0.651
H. pylori gastritis 83 (9.5) 23 (7.6) 0.320
Atrophy or metaplasia 130 (14.9) 61 (20.2) 0.032
TT triple therapy, SET sequential therapy, SD standard deviation, H. pylori
Helicobacter pylori, EGC early gastric cancer, MALT mucosa associated
lymphoid tissue
Fig. 2 Comparison of eradication rate of Helicobacter pylori with first-
line triple therapy with sequential therapy. The eradication rate of
SET was significantly higher than TT by both ITT (P = 0.001) and PP
(P = 0.002) analyses. TT triple therapy, SET sequential therapy, ITT
intention to treat, PP per protocol
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first-line TT was 71.0 and 84.0% by ITT and PP analysis;
eradication rate for BCQT-14 after TT was 85.3 and
95.5% by ITT and PP analysis, respectively. Twenty-four
(9.7%) patients failed at their first-line SET, and 22 pa-
tients received BCQT-14 which showed the eradication
rate of 72.7% in ITT and 84.2% in PP analysis. We found
no significant differences in the overall eradication rates,
compliance, adverse events between any of these three
groups (Table 4).
The most common complication after second-line
treatment was nausea or vomiting in all of three groups.
After failure of second-line eradication therapy in the
SET group, two patients refused further treatment, and
one patient received third-line eradication therapy con-
sisted with twice a day standard dose of PPI, amoxicillin
(1000 mg), and levofloxacin (500 mg) for 7 days. But,
eradication of H. pylori also failed after third-line
treatment.
Discussion
Our study revealed that the eradication rate of TT was
below the recommended threshold by both of ITT and
Table 2 Clinical factors related to successful Helicobacter pylori eradication
TT SET
OR 95% CI P value OR 95% CI P value
Univariate analyses
Male gender 0.941 0.637 – 1.391 0.761 1.039 0.436 – 2.477 0.932
Age < 50 years 0.724 0.481 – 1.089 0.121 1.634 0.702 – 3.807 0.255
Residence – Seoul 0.819 0.509 – 1.320 0.413 1.154 0.375 – 3.553 0.803
Alcohol 0.942 0.628 – 1.415 0..775 0.909 0.391 – 2.115 0.824
Smoking 0.883 0.553 – 1.411 0.602 0.802 0.329 – 1.955 0.628
Diabetes mellitus 1.375 0.770 – 2.455 0.281 1.190 0.330 – 4.289 0.790
Hypertension 0.933 0.579 – 1.502 0.775 1.131 0.426 – 2.999 0.805
Indication
Peptic ulcer disease 0.690 0.456 – 1.043 0.079 1.559 0.567 – 4.284 0.389
Malignant disease 0.647 0.297 – 1.410 0.273 1.604 0.461 – 5.581 0.458
Multivariate analysis
Male gender 0.941 0.635 – 1.394 0.761 1.013 0.419 – 2.449 0.976
Age < 50 years 0.718 0.476 – 1.083 0.114 1.708 0.717 – 4.068 0.227
Residence – Seoul 0.792 0.490 – 1.282 0.343 1.203 0.280 – 3.831 0.750
Indication
Peptic ulcer disease 0.679 0.447 – 1.030 0.069 1.538 0.554 – 4.272 0.409
Malignant disease 0.607 0.277 – 1.330 0.212 1.877 0.517 – 6.817 0.338
TT triple therapy, SET sequential therapy, OR odds ratio, CI confidence interval
Table 3 Adverse events during first-line Helicobacter pylori
eradication therapy
TT SET P value
N = 872 (74.3%) N = 302 (25.7%)
Total 33 (3.8) 10 (3.3) 0.706
Diarrhea 11 (1.3) 5 (1.7) 0.574
Nausea or vomiting 9 (1.0) 3 (1.0) 0.999
Abdominal pain 8 (0.9) 0 (0) 0.122
Skin rash 1 (0.1) 1 (0.3) 0.448
Metallic taste 1 (0.1) 0 (0) 0.999
Othersa 5 (0.6) 2 (0.7) 0.999
TT triple therapy, SET sequential therapy, H. pylori Helicobacter pylori
a Others included dyspepsia, bloating, and dizziness
Fig. 3 The flowchart of second-line treatment after failure of first-
line eradication therapy TT triple therapy, SET sequential therapy,
BCQT-7 bismuth-containing quadruple therapy for 7 days, BCQT-14
bismuth-containing quadruple therapy for 14 days
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PP analyses. This result is in accordance with the most
recent meta-analysis for treatment of H. pylori, which
concluded that SET was superior than TT showing the
overall eradication rate of TT for 69.8 and 77.0%, and
SET for 79.7 and 85.0% by ITT and PP analyses, respect-
ively [14]. The most important cause of decreased efficacy
of TT is considered as increasing antibiotic resistant rate,
especially to clarithromycin [21]. The eradication rate of
H. pylori was significantly different depending on the re-
sistance or sensitivity to clarithromycin of the strain;
67.9% for clarithromycin-resistant strains and 95.5% for
the clarithromycin-sensitive strains [12].
Previous studies proposed several clinical factors asso-
ciated with H. pylori eradication failure including, age,
gender, smoking, previous antibiotics usage [22, 23]. The
most recent study in Korea reported that female gender
could be associated with treatment failure, based on the
fact that H. pylori strain with point mutation in the 23S
rRNA were preferentially infected in women which
could result in treatment failure with clarithromycin
[24]. Also, smoking may increase treatment failure by re-
ducing antibiotics delivery to gastric mucosa, because
smoking decreases gastric blood flow and mucus
secretion and smoking itself is an indicator for poor
compliance [24–26]. However, we could not find any
statistically significant clinical factor to predict successful
eradication of H. pylori.
Our study supports SET as an alternative first-line
treatment for several reasons. First, SET achieved rea-
sonable target by both of ITT and PP analyses, whereas
TT showed unacceptable efficacy. The reason for rela-
tively higher efficacy of SET for H. pylori eradication
compared with TT could be based on decreased resist-
ance rate to metronidazole [27], because the resistance
to nitroimidazole reduces the efficacy of sequential ther-
apy up to 50% [21, 28, 29]. The resistance rate to metro-
nidazole was reported 40.5% during 1994–1999 [30],
49.6% between 2003 and 2005 [31], and 27.5% between
2003 and 2009 [12] in Korea. And clarithromycin
resistance is thought to have less effect on the efficacy of
SET than on TT [32]. Second, treatment-related adverse
events of SET were tolerable in most of the patients.
There was no patient who discontinued the treatment
due to treatment-related adverse event in our study.
Also, no significant differences were found regarding
overall complication rates or incidence of individual
complication between two groups. Third, drug compli-
ance in the SET group was comparable with that of the
TT group. There has been concern about complex ad-
ministration schedule and higher complication rates of
SET than TT [14] which could directly influence on
drug compliance and possibly lower drug efficacy. But,
our study revealed good compliance of the SET group,
almost 85.0%, which was not statistically different from
the TT group and showed no significant difference regard-
ing adverse events between the two groups. In our medical
center, all physicians explained possible treatment-related
complications before prescribing medication with suffi-
cient time, and this was also thought to be the cause of
good compliance of SET. Fourth, we suggested reasonable
treatment option in cases of treatment failure of first-line
SET. One of the major concerns of four-drug regimen is
choice of second-line treatment when first-line eradication
therapy failed, because there could be more chances of
acquiring antibiotic resistance [33]. According to the
Maastricht IV Consensus Report, BCQT is recommended
as optimal second-line treatment [34], and 2013 revised
Korean guidelines also recommends BCQT for second-
line option after failure of first-line TT [10]. However,
there is no definite guideline for the second-line treatment
after failure of SET. According to our results, BCQT could
be good second-line treatment option after failure of first-
line SET.
This study has several limitations. First, test for H. pyl-
ori identification or antibiotic sensitivity test was not
performed which could clarify direct influence of
antibiotic susceptibility on eradication rate. Antibiotic
resistance rate, especially clarithromycin resistance is
significant factor for determining the efficacy of H. pylori
eradication with TT or SET [24]. Thus, these kinds of
tests are the best way to reduce eradication failure aris-
ing from antibiotic resistance [21]. But, it is very difficult
to test all patients in the general clinics, and cost-
effectiveness is another problem [21]. In a recent
prospective study evaluating the efficacy of SET and
amoxicillin/tetracycline containing bismuth quadruple
therapy (PBAT) for the first-line eradication in the pa-
tients from nine different provinces, SET did not reach
the 90% eradication rate in the PP analysis despite SET
was more effective than PBAT [35]. This discordance with
our result could be explained by the difference of local
antibiotic resistance. In Korea, it has been reported that
antibiotics resistance of H. pylori is differ according to









Eradication rate, % (n)
ITT 71 (22/31) 85.3 (64/75) 72.7 (16/22) 0.162
PP 84 (21/25) 95.5 (64/67) 84.2 (16/19) 0.076
Compliance > 80%,
% (n)
80.6 (25) 89.3 (67) 86.4 (19) 0.511
Adverse events,
% (n)
25.8 (8) 22.7 (17) 18.2 (4) 0.839
TT triple therapy, SET sequential therapy, BCQT-7 bismuth-containing quadruple
therapy for 7 days, BCQT-14 bismuth-containing quadruple therapy for 14 days,
ITT intention to treat, PP per protocol
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the geographic region. In Seoul where our institution is
located, resistance rate to clarithromycin is known to
be 14.8%, however above study included the provinces
in which showed higher resistance rate compared to
Seoul such as Busan (42.1%) or Gyeonggi (32.5%) [27],
and that might be the cause for the decreased efficacy
of SET. The dicision for the appropriate empirical anti-
biotic therapy should be made based on the data of
recentlly updated local antibiotic resistance [11], and
therfore nationwide updated data for antibiotic resist-
ance of H. pylori should be surveyed.
Second, as this study was conducted retrospectively,
there were limitations to obtain detailed medical infor-
mation such as previous medication history including
antibiotics or PPI which could have an influence on
eradication failure or diagnosis of H. pylori infection.
Also, treatment-related adverse events in our study
might be down-estimated for the same reason. Com-
pared with previous studies which reported SET-related
adverse event rates from 23.3 [14] to 48.0% [32], there
was relatively small number of complications in our
study (3.3%).
Third, this study enrolled the patients only in the
single-center, and the majority of them resided in Seoul.
So applying the results of this study to another area
could have limitation. However, this study has strength
in terms of its large number of study subjects and as-
sessment of the efficacy of rescue therapy after failure of
first-line eradication therapy.
Conclusions
The eradication rate of TT was below the recommended
threshold. However, SET showed acceptable eradication
rate by both ITT (P = 0.001) and PP (P = 0.002) analyses
with comparable adverse events. SET also has reasonable
second-line treatment option, BCQT after failure of
first-line SET. Therefore, SET could be effective and tol-
erable candidate for the first-line H. pylori eradication
therapy.
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